<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075460</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-NHL-010</org_study_id>
    <nct_id>NCT05075460</nct_id>
  </id_info>
  <brief_title>Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma</brief_title>
  <official_title>A Prospective, Multicenter, Phase III, Non-randomized Study of Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined&#xD;
      with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tucidinostat, a novel histone deacetylase inhibitor has been approved for the treatment of&#xD;
      relapsed or refractory peripheral T-cell lymphoma in China. Azacytidine is a hypomethylating&#xD;
      agent. The aim of this study is to compare the efficacy and safety of azacytidine,&#xD;
      tucidinostat combined with CHOP regimen and classical CHOP regimen in the treatment of&#xD;
      primary PTCL&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>6 course of treatment (each cycle is 21 days)</time_frame>
    <description>the total proportion of patients with complete response (CR) and partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year progression-free survival（PFS）</measure>
    <time_frame>2 years</time_frame>
    <description>Time from treatment until disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year overall survival（OS）</measure>
    <time_frame>2 years</time_frame>
    <description>Time from treatment until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events, serious adverse events and other safety parameters</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the NCI CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Tucidinostat, Azacitidine combined with CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tucidinostat, Azacitidine combined with CHOP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHOP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucidinostat, Azacitidine combined with CHOP</intervention_name>
    <description>Azacitidine: 200 mg D1200 mg D2100 mg D3 subcutaneous injection Tucidinostat: 20mg / time, D1, 4, 8, 11; Take medicine with 200ml warm boiled water 30 minutes after breakfast.&#xD;
CHOP chemotherapy:&#xD;
Cyclophosphamide (CTX) 750mg / m2 intravenous infusion, day 1;&#xD;
Epirubicin (EPI) 70mg / m2 intravenous infusion, day 1;&#xD;
Vinoresin (VDS) 4mg intravenous infusion, day 1;&#xD;
Prednisone 100mg orally, day 1-5. Every 21 days is a course of treatment</description>
    <arm_group_label>CHOP</arm_group_label>
    <arm_group_label>Tucidinostat, Azacitidine combined with CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with peripheral T-cell lymphoma confirmed by primary pathology;&#xD;
&#xD;
          -  Age 18-70 years;&#xD;
&#xD;
          -  ECOG performance status ≤ 2;&#xD;
&#xD;
          -  Adequate bone marrow hematopoietic function: WBC &gt; 3.5 × 10*9/L，ANC&gt;1.5 ×&#xD;
             10*9/L，HGB&gt;90g/L，PLT&gt;80 × 10*9/L;&#xD;
&#xD;
          -  Adequate organ function: cardiac function grade 0-2 (NYHA); SpO2 &gt; 88% (natural&#xD;
             condition); ALT&lt;3UNL，TBil&lt;2ULN; SCr&gt;60ml/min/m2;&#xD;
&#xD;
          -  Patients have signed the Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ALK positive anaplastic T-cell lymphoma;&#xD;
&#xD;
          -  NK / T cell lymphoma, nasal type;&#xD;
&#xD;
          -  Uncontrolled active infection;&#xD;
&#xD;
          -  Acute myocardial infarction or unstable angina pectoris within 6 months; uncontrolled&#xD;
             hypertension, symptomatic arrhythmia, etc;&#xD;
&#xD;
          -  Subjects who are known or suspected to be unable to comply with the study protocol;&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daobin Zhou</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Hematology, Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Zhang</last_name>
    <phone>+861069156874</phone>
    <email>zhangyan10659@pumch.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daobin Zhou</last_name>
    <phone>+861069156874</phone>
    <email>zhoudb@pumch.cn</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>YanZhang</investigator_full_name>
    <investigator_title>Deputy Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Tucidinostat</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>CHOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

